ACG Invests $200M in First US Empty-Capsule Facility, Expanding Global Footprint

ACG, a leading supplier and service provider for solid dose drug manufacturers, has announced a significant investment of $200 million to establish its first empty-capsule production facility in the United States. This move marks a major expansion of the India-based company's global operations and strengthens its presence in the North American market.

$200M Investment in Atlanta Facility

The company plans to allocate an initial $100 million towards developing a hard-shell capsule site in Atlanta, Georgia. The remaining $100 million is earmarked for expanding capacity and capabilities in the region. Upon completion in early 2027, the facility will be capable of producing both gelatin and vegetarian hard-shell capsules, creating more than 200 jobs in the process.

Karan Singh, ACG's managing director, emphasized the strategic importance of this investment, stating, "This facility strengthens our ties with customers across the region—bringing us closer to them, enabling faster lead times, higher-quality service, and a more resilient, de-risked supply chain." Singh also highlighted the potential for enhanced innovation through closer R&D partnerships with regional customers.

Expanding US Presence and Global Operations

ACG has maintained a presence in the United States for over 25 years, with its North American headquarters located in Piscataway, New Jersey. The company currently operates a liquid-fill capsule facility in Chadds Ford, Pennsylvania, along with several warehouses and sales teams across the country.

This latest investment in Atlanta follows ACG's recent expansion in Asia, where the company announced the construction of a massive capsule production plant in Rayong, Thailand. The 1.89 million-square-foot facility, larger than 32 football fields, is designed to produce approximately 20 billion hard gelatin capsules annually and is expected to employ about 250 workers upon completion.

ACG's Growing Global Footprint

Founded in Mumbai, India, in 1961, ACG has spent more than six decades expanding its global reach. The company has positioned itself as a comprehensive solution provider for solid dosage production, covering various aspects from capsule manufacturing to protective packaging.

With these strategic investments in the United States and Thailand, ACG is solidifying its position as a global leader in the pharmaceutical manufacturing supply chain. The company's expansion not only enhances its production capabilities but also demonstrates its commitment to serving customers more efficiently across different regions.